INAB

0.75801.86%
LG

Luba Greenwood

Independent Director

Ms. Luba Greenwood, JD., was Independent Director of Traws Pharma, Inc. from September 16, 2024 until December 16, 2024. Ms. Greenwood serves as Chairman of the Board of Closed Loop Medicine Ltd. since September 2024. Since July 2024, Ms. Greenwood has served as chief executive officer and co-founder of Gallop Oncology. She has been Independent Non-Executive Director at Abcam plc since September 12, 2022. She has been Independent Director of IN8bio, Inc. since July 2021. She served as Chairman at Kojin Therapeutics Inc. since 2022 until November 2023. She served as Director at Kojin Therapeutics, Inc since June 2021 and served as Chief Executive Officer since October 2021until November 2023. She serves as Board Observer at Matchpoint Therapeutics, Inc. She serves as Director at BenchSci Analytics Inc. since July 2021. She served as a Senior Advisor at Grove Ventures Capital till June 2022. Luba also has legal knowledge in the fields of regulation, policy, data privacy and IP. Ms. Greenwood served as Venture Partner at Colt Ventures and led business development and strategy for Pronutria. She was Head of Strategic Business Development and Corporate Ventures at Google Life Sciences and Mergers & Acquisitions at F. Hoffmann-La Roche Ltd. where she established and led the East Coast Innovation Hub. She was Director of Entrinsic Bioscience, Inc until 2020. She is Board Advisor of Entrinsic Bioscience, Inc since 2020. Prior to that, Ms. Greenwood served as Senior Mergers & Acquisitions Counsel at Pfizer Inc. Ms. Greenwood is an adjunct professor at Boston University School of Management where she teaches business law and Boston University Law School where she teaches a course on life sciences. She is a veteran pharmaceutical and biotechnology industry, diagnostics, health devices, tech investor and company builder and has pharmaceutical and biotechnology industry experience, expertise in building innovative technology companies and providing strategic counsel to global corporations. Her career has spanned leadership roles in venture investing, business development, mergers & acquisitions, law, consulting and operations. She is an Independent Director of OS Acquisition Corp. Ms. Greenwood is a Managing Partner, Binney Street Capital LLC at Dana-Farber Cancer Institute, Inc. Previously, Ms. Greenwood served as Senior Advisor to the CEO at the Dana-Farber Institute, Vice President of Global Business Development and Mergers & Acquisitions at Roche, where she also established and led the East Coast Innovation Hub for the Diagnostics Division. Luba has led deals and investments across multiple therapeutic areas and life sciences and tech sectors globally. She has also co-founded biotech and digital health companies in the immunotherapy, women’s health and microbiome space, including Incysus and Luca Biologics. From February 2018 to July 2019, Ms. Greenwood was the head of strategic business development and corporate ventures for Verily Life Sciences LLC. Ms. Greenwood is on the Board of BenchSci and from April 2019 to December 2020, served as Advisor to the Dana-Farber Cancer Institute, as part of its Business Development Council, as well as the Wyss Center for Bio and Neuroengineering. Ms. Greenwood is a Thought Leader for the New England Journal of Medicine Catalyst, Founder of the Pharma Digital Health Roundtable and a Lecturer at Harvard University in the School of Engineering and Applied Sciences. Luba Greenwood is a Harvard Professor and investor in the Pharma and Digital Health and served in management roles at several companies. She served as Advisory Board Member at Catalyst Health Ventures till 2024. She had been a Director at Brooklyn ImmunoTherapeutics LLC. since March 2021 until January 1, 2022. Ms. Greenwood has served on the board of the Longwood Symphony Orchestra, is a co-chair of MassBioâs Entrepreneurs University, mentor for the MIT 100K Entrepreneurship Competition and a judge for MassChallenge and the Young Entrepreneurs Initiative. She serves on numerous boards, including the Massachusetts Biotechnology Council (MassBio). In 2014, she received the Science Club for Girls Catalyst Award for her commitment to fostering women talent and advocating for women in science and technology. She began her career at Wilmer Cutler Pickering Hale and Dorr as a litigator and regulatory, policy and intellectual property expert. Ms. Greenwood co-founded and was CEO of LUCA Biologics, Inc. since April 2019 until December 2021. She has a BA in Biology from Brandeis University and a JD from Northeastern University.

Positions